Drug data last refreshed Yesterday
IMITREX (sumatriptan) is an oral small-molecule serotonin 1B receptor agonist approved in 1995 for acute treatment of migraine, cluster headache, and post-traumatic headache. It works by constricting blood vessels and reducing substances in the body that cause headache, pain, sensitivity to light and sound, nausea, vomiting, and other symptoms of migraine.
As a legacy product approaching loss of exclusivity with modest Medicare spending, the brand team is likely consolidating and shifting focus to retention and generic channel management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Worked on IMITREX at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on IMITREX offers exposure to commercial execution and stakeholder management on a legacy franchise, but career upside is limited by LOE trajectory. Opportunities exist in MSL, market access, and generic channel roles, but high-growth assignments are concentrated on next-generation CGRP and novel migraine therapies.
19 open roles linked to this drug